The Effect of HMGB1 and HMGB2 on Transcriptional Regulation Differs in Neuroendocrine and Adenocarcinoma Models of Prostate Cancer

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Mar 28

PMID 38542079

Authors

Martin Salamini-Montemurri

Angel Vizoso-Vazquez

Aida Barreiro-Alonso

Lidia Lorenzo-Catoira

Esther Rodriguez-Belmonte

Maria-Esperanza Cerdan

Monica Lamas-Maceiras

Affiliations

Soon will be listed here.

Abstract

Human high-mobility group-B (HMGB) proteins regulate gene expression in prostate cancer (PCa), a leading cause of oncological death in men. Their role in aggressive PCa cancers, which do not respond to hormonal treatment, was analyzed. The effects of and silencing upon the expression of genes previously related to PCa were studied in the PCa cell line PC-3 (selected as a small cell neuroendocrine carcinoma, SCNC, PCa model not responding to hormonal treatment). A total of 72% of genes analyzed, using pre-designed primer panels, were affected. HMGB1 behaved mostly as a repressor, but HMGB2 as an activator. Changes in , , , and expression were validated using qRT-PCR after silencing or overexpression in PC-3 and LNCaP (selected as an adenocarcinoma model of PCa responding to hormonal treatment) cell lines. Similarly, the regulatory role of upon , , , , and expression was validated, finding differences between cell lines. The correlation between the expression of , , and their targets was analyzed in PCa patient samples and also in PCa subgroups, classified as neuroendocrine positive or negative, in public databases. These results allow a better understanding of the role of HMGB proteins in PCa and contribute to find specific biomarkers for aggressive PCa.

References

Song Z, Chao F, Zhuo Z, Ma Z, Li W, Chen G . Identification of hub genes in prostate cancer using robust rank aggregation and weighted gene co-expression network analysis. Aging (Albany NY). 2019; 11(13):4736-4756. PMC: 6660050. DOI: 10.18632/aging.102087. View

Lv D, Song X, Huang B, Yu Y, Shu F, Wang C . HMGB1 Promotes Prostate Cancer Development and Metastasis by Interacting with Brahma-Related Gene 1 and Activating the Akt Signaling Pathway. Theranostics. 2019; 9(18):5166-5182. PMC: 6691575. DOI: 10.7150/thno.33972. View

Ostano P, Mello-Grand M, Sesia D, Gregnanin I, Peraldo-Neia C, Guana F . Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma. Int J Mol Sci. 2020; 21(3). PMC: 7037893. DOI: 10.3390/ijms21031078. View

Chen J, Xu D, Wang T, Yang Z, Yang Y, He K . HMGB1 promotes the development of castration‑resistant prostate cancer by regulating androgen receptor activation. Oncol Rep. 2022; 48(5). PMC: 9535630. DOI: 10.3892/or.2022.8412. View

Tai S, Sun Y, Squires J, Zhang H, Oh W, Liang C . PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate. 2011; 71(15):1668-79. PMC: 3426349. DOI: 10.1002/pros.21383. View

Horoszewicz J, Leong S, Chu T, Wajsman Z, Friedman M, Papsidero L . The LNCaP cell line--a new model for studies on human prostatic carcinoma. Prog Clin Biol Res. 1980; 37:115-32. View

Elangovan I, Thirugnanam S, Chen A, Zheng G, Bosland M, Kajdacsy-Balla A . Targeting receptor for advanced glycation end products (RAGE) expression induces apoptosis and inhibits prostate tumor growth. Biochem Biophys Res Commun. 2011; 417(4):1133-8. DOI: 10.1016/j.bbrc.2011.12.060. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Zhou J, Chen X, Gilvary D, Tejera M, Eksioglu E, Wei S . HMGB1 induction of clusterin creates a chemoresistant niche in human prostate tumor cells. Sci Rep. 2015; 5:15085. PMC: 4606829. DOI: 10.1038/srep15085. View

10.

Suzuki S, Kato H, Fuji S, Naiki T, Naiki-Ito A, Yamashita Y . Early detection of prostate carcinogens by immunohistochemistry of HMGB2. J Toxicol Sci. 2018; 43(6):359-367. DOI: 10.2131/jts.43.359. View

11.

Koryakina Y, Knudsen K, Gioeli D . Cell-cycle-dependent regulation of androgen receptor function. Endocr Relat Cancer. 2015; 22(2):249-64. PMC: 4382102. DOI: 10.1530/ERC-14-0549. View

12.

Burdelski C, Strauss C, Tsourlakis M, Kluth M, Hube-Magg C, Melling N . Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer. Oncotarget. 2015; 6(10):8377-87. PMC: 4480759. DOI: 10.18632/oncotarget.3107. View

13.

Rustum Y . Thymidylate synthase: a critical target in cancer therapy?. Front Biosci. 2004; 9:2467-73. DOI: 10.2741/1408. View

14.

Carreras C, Santi D . The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem. 1995; 64:721-62. DOI: 10.1146/annurev.bi.64.070195.003445. View

15.

Slominski R, Raman C, Chen J, Slominski A . How cancer hijacks the body's homeostasis through the neuroendocrine system. Trends Neurosci. 2023; 46(4):263-275. PMC: 10038913. DOI: 10.1016/j.tins.2023.01.003. View

16.

Gnanasekar M, Thirugnanam S, Ramaswamy K . Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int J Oncol. 2009; 34(2):425-31. View

17.

Pan J, Ma Z, Liu B, Qian H, Shao X, Liu J . Identification of cancer-associated fibroblasts subtypes in prostate cancer. Front Immunol. 2023; 14:1133160. PMC: 10080037. DOI: 10.3389/fimmu.2023.1133160. View

18.

Barreiro-Alonso A, Camara-Quilez M, Salamini-Montemurri M, Lamas-Maceiras M, Vizoso-Vazquez A, Rodriguez-Belmonte E . Characterization of HMGB1/2 Interactome in Prostate Cancer by Yeast Two Hybrid Approach: Potential Pathobiological Implications. Cancers (Basel). 2019; 11(11). PMC: 6895793. DOI: 10.3390/cancers11111729. View

19.

Zhang Y, Lv F, Qiao L, Zhao Q . MiR-505 inhibits prostate cancer cell invasion, metastasis and epithelial-to-mesenchymal transition through targeting HMGB-1. J BUON. 2020; 25(4):2036-2044. View

20.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View